Search
Luliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalIt was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. … Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.
Penicillium camemberti
go.drugbank.com/drugs/DB10809ApprovedPenicillium camemberti is a fungus which can provoke allergic reactions. Penicillium camemberti extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixturePenicillium roqueforti
go.drugbank.com/drugs/DB10812ApprovedPenicillium roqueforti is a fungus which can provoke allergic reactions. Penicillium roqueforti extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureT-cell surface antigen CD2
go.drugbank.com/bio_entities/BE0000719TargetHumansCD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the si...
Synonyms: LFA-3 receptor, Rosette receptorInositol 1,4,5-trisphosphate-gated calcium channel ITPR3
go.drugbank.com/bio_entities/BE0009595TargetHumansInositol 1,4,5-trisphosphate-gated calcium channel that, upon 1D-myo-inositol 1,4,5-trisphosphate binding, transports calcium from the endoplasmic reticulum lumen to cytoplasm, thus releasing the intracellular calcium and therefore parti...
Synonyms: IP3 receptor isoform 3, Type 3 InsP3 receptorRespiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigationalthe accompanying vial of AS01E adjuvant as the adjuvant suspension component. … [L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalAs with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28]. … The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound [A32046].
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Interferon gamma-1b
go.drugbank.com/drugs/DB00033ApprovedInvestigationalProduction of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. … The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnIt is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. … Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline).